Search PubMed⌕ Search

Biomedical subjects

B Coiffier

Publications and source records attributed to B Coiffier.

At least 235 records · Page 13Linked to original sources
PubMed1985

[Severe quantitative bone marrow insufficiency: results of treatment with high-dose antilymphocyte serum].

Nineteen patients with severe aplastic anaemia were treated with 21 courses of horse antithymocyte globulins (ATG). Changes in haematological parameters were correlated with ATG dosage. One of the 11 patients who received less than 100 mg/kg is still alive after more than 12 months. One of the 10 patients who received more than 100 mg/kg died of infection; in the remaining 9 patients, treatment resulted in increase or even return to normal of haemoglobin, polymorphonuclear and platelet levels. None of these 9 patients relapsed during a median follow-up of 16 months (range: 7 to 35 months). Immediate drug tolerance and serum sickness were unrelated to ATG dosage. These results confirm the therapeutic effectiveness of antithymocytic globulins in severe aplastic anaemia; they also suggest that 150 mg/kg doses are required to obtain satisfactory and long-lasting results.

Adolescent↗
PubMed1985

Burkitt's lymphoma. Distinction of subgroups by morphometric analysis of the characteristics of 55 cell lines.

In an attempt to clarify the controversy about the distinction between Burkitt's and non-Burkitt's small noncleaved lymphomas, 55 cell lines derived from 48 Burkitt's lymphoma patients were characterized by morphometry on plastic-embedded sections. The results of the measurements permitted the identification of five main cytologic types, with regard to nuclear size, nuclear area dispersion and irregularity of nuclear profiles. The presence of the Epstein-Barr virus (EBV) and the geographic origin of the tumors seemed to play essential roles in the determination of nuclear size, with a significantly larger size seen in EBV-positive cell lines, and especially in the African lines among these. Immunoglobulin profile and monoclonal antibody expression also correlated with the nuclear size. Two conclusions may be drawn from this analysis. An in vivo transformation of the cells of Burkitt's lymphoma can be postulated to explain the wide morphologic spectrum of lymphomas presenting a rearrangement of chromosome 8. The fact that typical and atypical Burkitt's lymphomas cannot be differentiated by study of their derived cell lines raises the question as to the validity of the distinction between the two subtypes of small noncleaved lymphomas.

Africa↗
PubMed1984

[Association of mycosis fungoides and Hodgkin's disease].

A 69-year-old man developed a Hodgkin's disease 2 years after he started a mycosis fungoides. He presented cutaneous plaques of mycosis fungoides. The first signs of Hodgkin's disease was acquired ichthyosis and loss of weight. Echotomography of the abdomen showed retroperitoneal nodes. A laparotomy was performed and the histopathologic examination of the lymph nodes revealed a Hodgkin's disease type 2 (sclero-nodular). The liver and the bone marrow were involved. A chemotherapy was completed but the patient died 10 months later. The review of the literature showed 24 patients with Hodgkin's disease and mycosis fungoides or Sézary syndrome. Relation between mycosis fungoides, Hodgkin's disease and lymphomatoid papulosis are discussed.

Aged↗
PubMed1983

[Highly malignant non-Hodgkin's lymphoma. Treatment by intensive sequential chemotherapy].

Sixty-two patients with aggressive non-Hodgkin's lymphoma (diffuse mixed, diffuse large cells, non-cleaved small cells (Burkitt-like), immunoblastic, lymphoblastic and other non-epidermotropic T lymphomas) were treated by intensive sequential chemotherapy combining heavy induction treatment (modified CHOP-Bleo), sequential consolidation treatment (cytosine arabinoside and thioguanine, then high-dose methotrexate and L-asparaginase) and final reinforcement (CVAP-Bleo). Complete remission was achieved in 59 patients (95%); 11 patients (18%) relapsed. Two patients died during the induction phase and one failed to respond. Two patients died of an unrelated disease while in complete remission. Blood toxicity was tolerable and treatment could be conducted without problems in most cases. The median survival cannot be reached with a 14-months follow-up, but the survival rate seems to plateau at 70%. The only two prognostic factors identified were poor general condition and high serum lactate dehydrogenase levels.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1983

Dysmyelopoietic syndromes. A search for prognostic factors in 193 patients.

Dysmyelopoietic syndromes cover sideroblastic or nonsideroblastic refractory anemia with or without excess of blasts, subacute or chronic myelomonocytic leukemia. The evolution of 193 patients was studied with regard to the initial hematologic picture. A certain number of variables of prognostic value have then been isolated: excess of marrow blasts (more than 5%); presence of circulating blasts or karyotypic anomalies; reduction in the number of polymorphonuclear leukocytes (less than 1.043 10(9)/l, of monocytes (less than 0.136 10(9)/l), of platelets (less than 140 10(9)/l), of in vitro granulopoietic progenitors (less than 5 per 10(5) nucleated cells plated), of erythrocytic incorporation of 59Fe at day 14 (less than 12%), of hemoglobin level (less than 92 g/l); previous exposure to radiation or chemotherapy; early hemolysis in 51Cr-labeled erythrocytes study; marrow heterogeneity in histology; less than 20% of ringed sideroblasts. The correlation between these variables and adjustments related to the length of survival and the order of magnitude of the critical level of the log-rank test show that the most significant variables in descending order are: excess of marrow blasts, neutropenia, thrombopenia, presence of circulating blasts, the type of erythropoietic insufficiency, and decrease of in vitro growth.

Anemia, Sideroblastic↗
PubMed1982

[Prolonged survival in adults with acute myeloid leukemia treated with BCG immunotherapy].

Between november, 1974 and june, 1977, 64 adult patients with acute myeloid leukaemia in remission were divided at random into two treatment groups: chemotherapy alone (n = 32) or chemotherapy plus B.C.G. (n = 32). Fresh B.C.G. from the Pasteur Institute, Paris, was administered once a week, two or three times per month, in the intervals between chemotherapy cycles, using the Heaf-gun method. The duration of the first remission was significantly increased in the group receiving B.C.G. (median duration 685 days versus 390 days: p = 0.03 on log rank test) as was the overall survival (median duration of survival 1.471 days versus 554 days: p = 0.01). Second remissions were more frequent in the B.C.G. group (79% versus 42%; p = 0.014). In addition, prolonged survival was more frequent in the B.C.G. group, where 12/32 patients remained in first remission between 3 and 6 years, as against 5/32 in the chemotherapy group.

Adult↗
PubMed1982

[An empirical combination of antibiotics used in aplasias during chemotherapy for acute malignant hemopathies (author's transl)].

Continuous infusion of amikacin, cotrimoxazole and carbenicillin was the second empirically established combination of antibiotics used when fever occurred during the induction phase of chemotherapy in sixty-five patients (58 acute myeloid leukemias, 5 acute lymphoid leukemias, 2 non Hodgkin lymphomas). Clinical evidence of infection was available in 25 cases and the infection was bacteriologically documented in 19 cases. Therapy was successful in 57 patients (89%). When infection was clinically or bacteriologically documented tha success rates were 92 and 82% respectively. The average length of treatment was ten days. In 25 patients receiving 2 g of amikacin in continuous infusion, the mean serum concentration was 15,9 micrograms/ml; in 17 patients receiving 3 g, the mean serum concentration was 19,4 micrograms/ml.

Adult↗
PubMed1982

Agar culture of bone marrow cells in acute myeloid leukemia and dysmyelopoietic syndromes. Reevaluation of its prognostic value.

The expression of results obtained in in vitro bone marrow cell culture as per ml of aspirated marrow instead of per 10(5) nucleated cells plated as studied in 41 patients with acute myeloid leukemia (AML) and 79 patients with a dysmyelopoietic syndrome. Four types of growth were found in AML patients: three with hypercellular marrow and either (a) microclusters, (b) isolated cells, or (c) macroclusters and a complete remission (CR) rate of 86%, 63%, and 14% respectively; (d) relative hypocellular marrow with a CR rate of 0%. This type of poorly responsive AML patient has recently been described [17]. Patients with dysmyelopoietic syndromes were subdivided into three groups according to th type of in vitro growth: subnormal, decreased, and leukemic. There was a good correlation between these in vitro groups and the outcome of patients: long survival, death from hemorrhagic and/or infectious complications, leukemic transformation (logrank test: chi 2 = 9.12, df = 2, p = 0.01).

Adult↗
PubMed1981

[Pure red cell aplasia and chronic leukemia. Usefulness of ferrokinetic measurements (author's transl)].

Erythroblastopenia is probably not rare in chronic lymphocytic leukemia (CLL) but the diagnosis could be difficult. It produces a severe and rapidly developing anemia, without evidence of hemolysis. The chief differential diagnosis is the common bone marrow insufficiency of end-stage CLL. Iron kinetics measurements are typical, showing a total erythropoietic insufficiency, and a red cell utilization of radio-iron that is practically zero. Erythroblastopenia could be cured with corticosteroid or sometimes with immunosuppressive treatment.

Adult↗
PubMed1980

[In vitro culture of granulopoietic precursors in dysmyelopoiesis. Prognostic value (author's transl)].

96 patients with a dysmyelopoiesis have had an in vitro study of bone marrow CFUc at the time of diagnosis. A correlation between in vitro growth characteristics and the transformation in acute leukemia (AT) was searched. We found 5 types of in vitro growth: 3 with a "non-leukemic" pattern IA, IB, and IC, and 2 with a "leukemic" pattern II and III. In the type IA (normal growth) there is few death (16%), all without AT. In the types IB and ic with decreased in vitro growth, 40% of patients dead without an at and 25% after an AT. In the types II (with excess of clusters) and III (clusters without colonies) an AT was almost the case. The specificity, the positive and negative predictive values of in vitro growth type for the study of an AT outcome were the best of all that we obtained in the study of biological parameters in the dysmyelopoiesis. The study of bone marrow CFUc in dysmyelopoiesis can separate a group of patients with high risk of an AT outcome, which could be ameliorate with chimiotherapy.

Adult↗